ClinicalTrials.gg

Burns clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 906 studies for Burns across more than 10 countries. 165 are recruiting or about to start. 782 of them are mainly about Burns (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Sunburn too: 935 studies, 167 open.

ClinicalTrials.gov finds 1,235 studies for Burns. How that becomes 903 here

This page counts the studies the registry files under Burns, and those it files under no condition that list Burnsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,235Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −29Filed under a narrower condition, counted on its own pageSunburn 29
  3. −133List Burns as a condition, but the registry did not file them under itMost often written as “Burn Out” (22), “Burn Scar” (13), and “Fat Burn” (12). The registry filed them under other conditions only, most often Burnout, Psychological (37) and Anxiety Disorders (11).
  4. −170Match it another way130 name it in the title, 22 in a keyword, and 18 by a synonym or other text the search reads.
  5. 903The count on this page139 of them list Burns in their own words; the registry filed them under no condition.

Status

Completed
433
Status unknown
114
Terminated
93
Recruiting
85
Withdrawn
73
Not yet recruiting
64

Phase

Phase 2
111
Phase 3
72
Phase 1
61
Phase 4
52
Early Phase 1
12

Where

United States
336
Egypt
66
Turkey
43
Canada
42
France
32
Germany
27

Who develops what

Add Burns to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 4 companies, 3 with this as their studies’ main aim; 3 with a live phase 3 study; 2 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ChymotrypsinRecent, limited
Evidence
  • NCT07025408 · Shanghai Bao Pharmaceuticals Co., Ltd. · Phase 2 · live · comparator · “Chymotrypsin” · registered Jun 2025
—11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Jun 2027 est.denovoSkin(TM) · CUTISS AG · Phase 3 main aimNCT06745557 Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents — primary endpoint: A composite endpoint whereby success is defined by meeting both of the following criteria: - Wound closure - Scar quality (POSAS v2.0) · 70 enrolled
  • Sep 2027 est.IP2 - 0.5% w/w FS2 · Birch BioMed Inc · Phase 3 main aimNCT06807021 Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients — primary endpoint: Scar condition of the skin grafted wound on Day 90 as assessed by VSS · 70 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Burns studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 1 open · Beta-lactamase inhibitors 1 open · Beta blockers 9 · Opioids 6 · Androgens 4

Coming up

36studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger. 17 (20%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 10 (12%) take healthy volunteers.

Recruiting studies that take each age, of 85
AgeWomenMen
1013 (15%)13 (15%)
1869 (81%)70 (82%)
3076 (89%)77 (91%)
4075 (88%)76 (89%)
5075 (88%)75 (88%)
6570 (82%)70 (82%)
7553 (62%)53 (62%)
8541 (48%)41 (48%)

Across all 906 studies, recruiting or not: 48% stop at 75 or younger and 39% at 65; 33% take children; 1% are for women only and 1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Burns studies take

Of 21 phase 3 interventional studies under Burns, half reached primary completion within 25 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 233 mo11–61 · 17 studies——
Phase 325 mo13–59 · 21 studies——
Phase 429 mo25–43 · 21 studies——
Interventional, no phase15 mo6–38 · 240 studies11 mo8–27 · 29 studies18 mo6–38 · 211 studies
Observational24 mo14–56 · 68 studies—26 mo14–56 · 56 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 906. Browse all 906 → or search them.